Related Experiment Video
Updated: Apr 18, 2026
Direct Vagus Nerve Injection Protocol For Rats
Published on: March 14, 2025
Intrathecal injection of lentivirus-mediated glial cell line-derived neurotrophic factor RNA interference relieves
Fu-Fen Meng1, Yang Xu, Qi-Qin Dan
1Department of Anesthesia, Xinjiang Tumor Hospital, Urumqi, China.
Abstract:
Bone cancer pain is a common symptom in cancer patients with bone metastases and the underlying mechanisms are largely unknown. The aim of this study is to explore the endogenous analgesic mechanisms to develop new therapeutic strategies for bone-cancer induced pain (BCIP) as a result of metastases. MRMT-1 tumor cells were injected into bilateral tibia of rats and X-rays showed that the area suffered from bone destruction, accompanied by an increase in osteoclast numbers. In addition, rats with bone cancer showed apparent mechanical and thermal hyperalgesia at day 28 after intratibial MRMT-1 inoculation. However, intrathecal injection of morphine or lentivirus-mediated glial cell line-derived neurotrophic factor RNAi (Lvs-siGDNF) significantly attenuated mechanical and thermal hyperalgesia, as shown by increases in paw withdrawal thresholds and tail-flick latencies, respectively. Furthermore, Lvs-siGDNF interference not only substantially downregulated GDNF protein levels, but also reduced substance P immunoreactivity and downregulated the ratio of pERK/ERK, where its activation is crucial for pain signaling, in the spinal dorsal horn of this model of bone-cancer induced pain. In this study, Lvs-siGDNF gene therapy appeared to be a beneficial method for the treatment of bone cancer pain. As the effect of Lvs-siGDNF to relieve pain was similar to morphine, but it is not a narcotic, the use of GDNF RNA interference may be considered as a new therapeutic strategy for the treatment of bone cancer pain in the future.
Insights
Glial cell line-derived neurotrophic factor RNA interference (GDNF RNAi) effectively reduced bone cancer pain in rats by targeting pain signaling pathways. This non-narcotic gene therapy shows promise as a novel treatment for bone metastasis pain.
Area of Science:
- Oncology
- Pain Management
- Gene Therapy
Background:
- Bone cancer pain is a prevalent and debilitating symptom in patients with bone metastases.
- The precise mechanisms underlying bone cancer pain remain largely unknown, hindering effective treatment development.
Purpose of the Study:
- To investigate endogenous analgesic mechanisms for developing novel therapeutic strategies for bone-cancer induced pain (BCIP).
- To evaluate the efficacy of glial cell line-derived neurotrophic factor RNA interference (Lvs-siGDNF) in alleviating BCIP.
Main Methods:
- MRMT-1 tumor cells were inoculated into rat tibias to establish a bone cancer pain model.
- Mechanical and thermal hyperalgesia were assessed, and treatments included intrathecal morphine and Lvs-siGDNF.
- Spinal dorsal horn analyses examined GDNF protein levels, substance P, and ERK/pERK signaling.
Main Results:
- Bone destruction and increased osteoclasts were observed in the tumor-bearing tibias.
- Both morphine and Lvs-siGDNF significantly reduced mechanical and thermal hyperalgesia.
- Lvs-siGDNF downregulated GDNF, substance P, and the pERK/ERK ratio, indicating reduced pain signaling.
Conclusions:
- Lvs-siGDNF gene therapy demonstrated significant pain relief in a rat model of bone cancer pain.
- GDNF RNA interference offers a potential non-narcotic therapeutic strategy for managing bone cancer pain, comparable in efficacy to morphine.
